JPMorgan builds $2.93 billion stake in health care stock

JPMorgan Chase conscionable planted a massive $2.93 cardinal flag successful possibly 1 of the hottest corners of the market.

The large bank’s concern limb disclosed a whopping multibillion-dollar involvement successful Eli Lilly (LLY) in its caller 13F filing, making it the stand-out summation successful its power-packed portfolio.

The pertinent determination has everything to bash with the GLP-1 revolution.

Eli Lilly, successful particular, has ridden the weight-loss question into a people of its own.

For perspective, implicit the past fewer months, it concisely crossed the $1 trillion marketplace cap threshold, CNBC reported, with Mr. Market going all-in connected the ubiquitous obesity and diabetes manufacture reshaping planetary wellness care.

Over the past six months, Eli Lilly banal has rewarded investors handsomely, delivering a 58% gain.

However, since I past covered Eli Lilly connected Dec. 20, 2025, it’s down astir 3%.

At the aforesaid time, Lilly has been delivering multibillion-dollar quarters, powered by surging request for Mounjaro and Zepbound.

Moreover, marketplace estimates peg the obesity cause marketplace astatine $100 cardinal by 2030, with Lilly dominating it.

So clearly, JPMorgan’s multibillion-dollar allocation aligns with what appears to beryllium a large structural displacement successful medicine and user behavior.

• Market value: $1.59 trillion (prior: $1.67 trillion)

• Inflows (outflows) arsenic percent of full MV: 6.26%

• New purchases: 638 stocks

• Added to: 2,643 stocks

• Sold retired of: 605 stocks

• Reduced holdings in: 3,425 stocks

• Top 10 holdings concentration: 26.3%

• Turnover: 15.6%

• Turnover (alt): 5.5%
  Source: WhaleWisdom

The GLP-1 motor has been humming on exceptionally well, and Eli Lilly’s results intelligibly bespeak that.

In Q4 2025, Eli Lilly generated an eye-popping $19.3 cardinal successful sales, up 43% twelvemonth implicit year, and posted $7.54 successful adjusted EPS, beating expectations by a comfy margin.

More Wall Street

• Top expert bets these stocks volition boost your portfolio successful 2026

• Billionaire Dalio sends 2-words connected Fed prime Warsh

• Bank of America sends quiescent informing to banal marketplace investors

Mounjaro brought successful astir $7.4 billion, portion Zepbound added astir $4.3 billion.

As we look ahead, things are lone going to get much lucrative, with Lilly guiding to $80 cardinal to $83 cardinal successful sales and $33.50 to $35.00 successful EPS, leaning heavy connected the relentless request for obesity and diabetes treatments.

• Goldman Sachs expects the planetary anti-obesity cause marketplace to leap to roughly $95 cardinal by 2030, spearheaded by GLP-1 therapies.

• JPMorgan forecasts the broader GLP-1 marketplace to rise to $100 cardinal by 2030, divided betwixt diabetes and obesity demand.

• Morgan Stanley projects that the obesity-drug marketplace could scope nearly $150 cardinal by 2035.